title: [Autologous hematopoietic stem cell transplantation for the treatment of aggressive non-Hodgkin's lymphoma. The experience of Polish lymphoma research group].
abstract: We analysed the outcome of 200 patients, aged 38 (13-72) years, with aggressive non-Hodgkin's lymphoma (NHL) treated with high-dose chemotherapy followed by autologous haematopoietic stem cell transplantation (autoHSCT) in ten oncohaematological centres belonging to Polish Lymphoma Research Group (PLRG). The source of stem cells for transplantation was peripheral blood (autoPBSCT, n = 153), bone marrow (autoBMT, n = 40) or both blood and bone marrow (n = 7). The probability of overall survival (OS) and progression-free survival at 10 years was 51% (+/- 7%). The transplant-related mortality rate equalled 7%. In multivariate analysis, the only factor influencing independently the probability of OS was disease status at transplantation (p < 0.00001). The outcome of patients transplanted in first or subsequent complete remission or first partial remission (PR) was significantly better compared with subjects given autoHSCT in PR 2 or those with primary or secondary refractoriness. Regarding histological subtypes, the highest OS rate (87%) was observed for anaplastic large T cell lymphoma. The outcome after autoBMT was better compared with autoPBSCT (OS probability: 67% vs. 43%), although the difference did not reach statistical significance. We conclude that high-dose therapy followed by autoHSCT is an effective option for high-risk aggressive NHL. Remission status is a major factor determining long-term outcome. This should be taken into account when referring patients for autoHSCT.
authors.affiliation: Katedra i Klinika Hematologii i Transplantacji Szpiku Sl. AM w Katowicach.
authors.forename: Jerzy
authors.initials: J
authors.lastname: Hołowiecki
authors.forename: Sebastian
authors.initials: S
authors.lastname: Giebel
authors.forename: Jan
authors.initials: J
authors.lastname: Walewski
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Krawczyk-Kuliś
authors.forename: Andrzej
authors.initials: A
authors.lastname: Hellmann
authors.forename: Aleksander
authors.initials: A
authors.lastname: Skotnicki
authors.forename: Anna
authors.initials: A
authors.lastname: Dmoszyńska
authors.forename: Joanna
authors.initials: J
authors.lastname: Romejko
authors.forename: Jarosław
authors.initials: J
authors.lastname: Czyz
authors.forename: Wojciech
authors.initials: W
authors.lastname: Jurczak
authors.forename: Łucja
authors.initials: Ł
authors.lastname: Kachel
authors.forename: Jerzy
authors.initials: J
authors.lastname: Wojnar
authors.forename: Beata
authors.initials: B
authors.lastname: Stella-Hołowiecka
authors.forename: Maria
authors.initials: M
authors.lastname: Saduś-Wojciechowska
authors.forename: Kazimierz
authors.initials: K
authors.lastname: Sułek
authors.forename: Wiesław
authors.initials: W
authors.lastname: Jedrzejczak
authors.forename: Tadeusz
authors.initials: T
authors.lastname: Robak
authors.forename: Bozena
authors.initials: B
authors.lastname: Mariańska
authors.forename: Cezary
authors.initials: C
authors.lastname: Szczylik
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Warzocha
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D014182:Transplantation, Autologous